A Multiregion, Randomized, Controlled, Blinded Study of the Safety and Efficacy of Bone Healing Accelerant Versus Standard of Care in Subjects With Open Tibia Fractures
Latest Information Update: 12 Feb 2024
Price :
$35 *
At a glance
- Drugs CT 101-carmell corporation (Primary)
- Indications Fracture
- Focus Registrational; Therapeutic Use
- Sponsors Carmell Corporation
- 06 Feb 2024 Planned End Date changed from 1 Sep 2022 to 1 Sep 2028.
- 06 Feb 2024 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2028.
- 06 Feb 2024 Planned initiation date changed from 1 Jul 2020 to 1 Jul 2026.